BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32009426)

  • 1. Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy.
    Lim CY; Liu X; He F; Liang H; Yang Y; Ji T; Yang R; Guo W
    Bone Joint J; 2020 Feb; 102-B(2):177-185. PubMed ID: 32009426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
    Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
    Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
    Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
    J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery.
    Xu W; Wang Y; Wang J; Yang X; Liu W; Zhou W; Liu T; Xiao J
    J Neurosurg Spine; 2017 Jun; 26(6):716-721. PubMed ID: 28338455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for the local recurrence of giant cell tumours of the sacrum treated with nerve-sparing surgery.
    Zhao Y; Tang X; Yan T; Ji T; Yang R; Guo W
    Bone Joint J; 2020 Oct; 102-B(10):1392-1398. PubMed ID: 32993346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
    Agarwal MG; Gundavda MK; Gupta R; Reddy R
    Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum.
    Tsukamoto S; Ali N; Mavrogenis AF; Honoki K; Tanaka Y; Spinnato P; Donati DM; Errani C
    BMC Musculoskelet Disord; 2021 Dec; 22(1):1023. PubMed ID: 34872538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
    J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.
    Bukata SV; Blay JY; Rutkowski P; Skubitz K; Henshaw R; Seeger L; Dai T; Jandial D; Chawla S
    Spine (Phila Pa 1976); 2021 Mar; 46(5):277-284. PubMed ID: 33038190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
    Puri A; Gulia A; Hegde P; Verma V; Rekhi B
    Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
    Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab.
    Yang Y; Li Y; Liu W; Xu H; Niu X
    Medicine (Baltimore); 2018 Nov; 97(46):e13139. PubMed ID: 30431583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.